Suchergebnisse - "De Giorgi, Ugo"

PubPharm (596)

81

Addition of Niraparib to Best Supportive Care as Maintenance Treatment in Patients with Advanced Urothelial Carcinoma Whose Disease Did Not Progress After First-line Platinum-based Chemotherapy : The Meet-URO12 Randomized Phase 2 Trial

enthalten in: European urology | 2023

von Vignani, F. | Tambaro, R. | De Giorgi, U. | +22

82

Impact of the time interval between primary or interval surgery and adjuvant chemotherapy in ovarian cancer patients

enthalten in: Frontiers in oncology | 2023

von Farolfi, A. | Petracci, E. | Gurioli, G. | +13

83

KEYNOTE-991 : pembrolizumab plus enzalutamide and androgen deprivation for metastatic hormone-sensitive prostate cancer

enthalten in: Future oncology (London, England) | 2023

von Gratzke, C. | Kwiatkowski, M. | De Giorgi, U. | +6

84

Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment : real-world evidence from CaRe, a multicentric, observational study

enthalten in: Frontiers in oncology | 2023

von Di Lisa, F. | Krasniqi, E. | Pizzuti, L. | +81

85

Current State and Future Challenges for PI3K Inhibitors in Cancer Therapy

enthalten in: Cancers | 2023

von Sirico, M. | D'Angelo, A. | Gianni, C. | +3

86

Corrigendum : Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma

enthalten in: Frontiers in oncology | 2023

von Lorusso, D. | Danesi, R. | Locati, L. | +9

ErratumFor: Front Oncol. 2022 Sep 21;12:979519. - PMID 36212444

87

Immune checkpoint inhibitors and Chimeric Antigen Receptor (CAR)-T cell therapy : Potential treatment options against Testicular Germ Cell Tumors

enthalten in: Frontiers in immunology | 2023

von Schepisi, G. | Gianni, C. | Cursano, M. | +8

88

Clinical outcomes of volume of disease on patients receiving enzalutamide versus abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer

enthalten in: Therapeutic advances in medical oncology | 2023

von Nuzzo, P. | Ravera, F. | Saieva, C. | +16

ErratumIn: Ther Adv Med Oncol. 2023 Jun 16;15:17588359231182232. - PMID 37342256

89

Serum Mass Spectrometry Proteomics and Protein Set Identification in Response to FOLFOX-4 in Drug-Resistant Ovarian Carcinoma

enthalten in: Cancers | 2023

von D'Arca, D. | Severi, L. | Ferrari, S. | +15

90

Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma : NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a)

enthalten in: International journal of molecular sciences | 2023

von Stellato, M. | Buti, S. | Maruzzo, M. | +18